Connection

Richard Drake to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications Richard Drake has written about Biomarkers, Tumor.
Richard Drake
Connection Strength
5.062
Biomarkers, Tumor
  1. Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues. Mol Cell Proteomics. 2021; 20:100012.
    View in: PubMed
    Score: 0.543
  2. How else can we approach prostate cancer biomarker discovery? Expert Rev Mol Diagn. 2020 02; 20(2):123-125.
    View in: PubMed
    Score: 0.498
  3. Mass Spectrometry Imaging in Cancer Research: Future Perspectives. Adv Cancer Res. 2017; 134:283-290.
    View in: PubMed
    Score: 0.413
  4. MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues. Adv Cancer Res. 2017; 134:85-116.
    View in: PubMed
    Score: 0.412
  5. Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9.
    View in: PubMed
    Score: 0.381
  6. MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics. 2014 Apr; 14(7-8):924-35.
    View in: PubMed
    Score: 0.340
  7. The proteomics of prostate cancer exosomes. Expert Rev Proteomics. 2014 Apr; 11(2):167-77.
    View in: PubMed
    Score: 0.339
  8. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res. 2010 May 07; 9(5):2109-16.
    View in: PubMed
    Score: 0.261
  9. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope. 2008 Jan; 118(1):61-8.
    View in: PubMed
    Score: 0.222
  10. Proteomic approach to breast cancer. Cancer Control. 2007 Oct; 14(4):360-8.
    View in: PubMed
    Score: 0.218
  11. Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg. 2007 May; 204(5):1065-71; discussion 1071-3.
    View in: PubMed
    Score: 0.211
  12. Glycan Imaging Mass Spectrometry: Progress in Developing Clinical Diagnostic Assays for Tissues, Biofluids, and Cells. Clin Lab Med. 2021 06; 41(2):247-266.
    View in: PubMed
    Score: 0.139
  13. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clin Cancer Res. 2021 01 01; 27(1):226-236.
    View in: PubMed
    Score: 0.135
  14. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. Clin Cancer Res. 2019 05 01; 25(9):2745-2754.
    View in: PubMed
    Score: 0.119
  15. Characterization and Evidence of the miR-888 Cluster as a Novel Cancer Network in Prostate. Mol Cancer Res. 2018 04; 16(4):669-681.
    View in: PubMed
    Score: 0.111
  16. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Sci Rep. 2017 06 22; 7(1):4020.
    View in: PubMed
    Score: 0.107
  17. Proteomic Profiling of Serial Prediagnostic Serum Samples for Early Detection of Colon Cancer in the U.S. Military. Cancer Epidemiol Biomarkers Prev. 2017 05; 26(5):711-718.
    View in: PubMed
    Score: 0.103
  18. miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle. 2014; 13(2):227-39.
    View in: PubMed
    Score: 0.083
  19. Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Mol Cell Proteomics. 2011 Jun; 10(6):M110.007294.
    View in: PubMed
    Score: 0.069
  20. Challenges to developing proteomic-based breast cancer diagnostics. OMICS. 2011 May; 15(5):251-9.
    View in: PubMed
    Score: 0.069
  21. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res. 2009 Sep 01; 15(17):5541-51.
    View in: PubMed
    Score: 0.062
  22. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009 May; 208(5):970-8; discussion 978-80.
    View in: PubMed
    Score: 0.060
  23. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res. 2009 Feb; 8(2):620-30.
    View in: PubMed
    Score: 0.060
  24. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol. 2004 Oct; 11(10):907-14.
    View in: PubMed
    Score: 0.044
  25. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 2012 Dec; 11(12):1870-84.
    View in: PubMed
    Score: 0.019
  26. MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem. 2011 Jul; 401(1):17-27.
    View in: PubMed
    Score: 0.017
  27. Molecular pathology of prostate cancer. Cancer Biomark. 2010; 9(1-6):441-59.
    View in: PubMed
    Score: 0.016
  28. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. 2004 May 01; 100(9):1814-22.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.